CA2658559A1 - Induction de reponses immunes cellulaires au virus de la grippe grace a des compositions de peptides et d'acides nucleiques - Google Patents
Induction de reponses immunes cellulaires au virus de la grippe grace a des compositions de peptides et d'acides nucleiques Download PDFInfo
- Publication number
- CA2658559A1 CA2658559A1 CA002658559A CA2658559A CA2658559A1 CA 2658559 A1 CA2658559 A1 CA 2658559A1 CA 002658559 A CA002658559 A CA 002658559A CA 2658559 A CA2658559 A CA 2658559A CA 2658559 A1 CA2658559 A1 CA 2658559A1
- Authority
- CA
- Canada
- Prior art keywords
- epitope
- polynucleotide
- hla
- epitopes
- htl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83211206P | 2006-07-21 | 2006-07-21 | |
US60/832,112 | 2006-07-21 | ||
PCT/US2007/016529 WO2008039267A2 (fr) | 2006-07-21 | 2007-07-23 | Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2658559A1 true CA2658559A1 (fr) | 2008-04-03 |
Family
ID=39230737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002658559A Abandoned CA2658559A1 (fr) | 2006-07-21 | 2007-07-23 | Induction de reponses immunes cellulaires au virus de la grippe grace a des compositions de peptides et d'acides nucleiques |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2069376A4 (fr) |
AU (1) | AU2007300663A1 (fr) |
CA (1) | CA2658559A1 (fr) |
WO (1) | WO2008039267A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11111277B2 (en) | 2016-12-28 | 2021-09-07 | Invvax, Inc. | Influenza vaccines |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA017957B1 (ru) | 2007-06-25 | 2013-04-30 | Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд | Композиции и способы, ингибирующие грипп |
DK2173376T3 (en) * | 2007-08-02 | 2015-06-29 | Biondvax Pharmaceuticals Ltd | Multimeric multi-epitope influenza vaccines |
EP2296688A2 (fr) * | 2007-10-26 | 2011-03-23 | Glykos Finland Oy | Vaccin peptidique contre le virus de la grippe |
FI20080333A0 (fi) * | 2008-05-02 | 2008-05-02 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
EP2353610A4 (fr) * | 2008-11-19 | 2013-12-11 | Avi Mex S A De C V Lab | Vaccin recombinant à vecteur viral inactivé |
US8282938B2 (en) * | 2008-11-28 | 2012-10-09 | National Institute Of Infectious Diseases | Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain |
WO2010086294A2 (fr) | 2009-01-28 | 2010-08-05 | Epimmune Inc. | Polypeptides de liaison de pan-dr et leurs utilisations |
CA2750922A1 (fr) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Peptides hybrides li-key modulant la reponse immunitaire a la grippe |
CN101792745B (zh) | 2009-02-04 | 2014-09-17 | 中国科学院生物物理研究所 | 流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构 |
CN101565455B (zh) * | 2009-05-25 | 2012-03-14 | 中国科学院微生物研究所 | 禽流感h5n1病毒的ctl表位多肽及其应用 |
CA2761733C (fr) * | 2009-06-01 | 2019-01-08 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Reactifs et procedes de detection de proteines du virus de la grippe |
US8865182B2 (en) | 2009-07-31 | 2014-10-21 | Paxvax, Inc. | Adenoviral-based vectors |
CA2775720A1 (fr) * | 2009-09-30 | 2011-04-07 | Saint Louis University | Peptides declenchant des reponses hetero sous-typiques des lymphocytes t contre la grippe |
CN102153621B (zh) * | 2010-02-12 | 2014-07-02 | 广东省疾病预防控制中心 | 新型甲型h1n1流感na蛋白b细胞表位及其应用 |
EP2536747B1 (fr) | 2010-02-19 | 2017-09-27 | Université de Liège | Un polynucleotide pour l'utilisation dans les traitements de maldies induites par des virus influenza a virus, codant pour une proteine modifiee, cette proteine modifiee et un animal transgénique exprimant un gène codant pour cette protéine modifiée |
WO2011138032A2 (fr) * | 2010-05-05 | 2011-11-10 | Artemev, Timur | Vaccins antigrippaux universels et leurs procédés de production |
WO2012040127A1 (fr) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Analogues nucléotidiques substitués |
CA2828068C (fr) | 2011-02-22 | 2019-03-19 | Biondvax Pharmaceuticals Ltd. | Polypeptides multimeres multi-epitopes utilises dans des vaccins contre la grippe saisonniere et pandemique |
US20140302124A1 (en) * | 2011-10-19 | 2014-10-09 | Immunotape, Inc. | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION |
CA2860234A1 (fr) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Analogues de nucleotide phosphorothioate substitue |
WO2013093514A2 (fr) * | 2011-12-23 | 2013-06-27 | Retroscreen Virology Ltd | Vaccins - peptides |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
MX2015008847A (es) * | 2013-01-10 | 2015-10-30 | Novartis Ag | Composiciones inmunogenicas de virus de influenza y usos de las mismas. |
CN103333224B (zh) * | 2013-05-10 | 2015-03-25 | 中国农业科学院哈尔滨兽医研究所 | 禽流感病毒ns1蛋白b细胞抗原表位多肽及其应用 |
WO2015186721A1 (fr) * | 2014-06-03 | 2015-12-10 | 国立研究開発法人農業・食品産業技術総合研究機構 | Anticorps ou fragment d'anticorps comprenant une région variable de celui-ci, polypeptide antigénique et utilisations de ceux-ci |
CN106589105B (zh) * | 2017-01-23 | 2020-09-15 | 中国医科大学 | Hla-a2限制性ecm1特异性的ctl表位肽及其应用 |
US11517617B2 (en) | 2017-09-08 | 2022-12-06 | The University Of Melbourne | Methods and compositions for preventing influenza infection |
EP3851120A4 (fr) * | 2018-09-11 | 2022-04-27 | Shanghai Public Health Clinical Center | Immunogène pour vaccin à large spectre contre la grippe, et application de celui-ci |
EP4168428A1 (fr) * | 2020-06-19 | 2023-04-26 | Intervet International B.V. | Vaccin contre le virus de la grippe porcine comprenant une construction d'acide nucléique codant pour des antigènes de lignées de virus spécifiques |
JP2023530134A (ja) * | 2020-06-19 | 2023-07-13 | インターベット インターナショナル ベー. フェー. | ウイルスの別々のノイラミニダーゼ抗原をエンコードする第1、第2および第3の核酸配列を含む核酸構築物を含むブタインフルエンザaウイルスワクチン |
WO2022032274A1 (fr) * | 2020-08-02 | 2022-02-10 | Richard Ascione | Compositions de vaccins contre les virus de la grippe et méthodes d'utilisation |
JP2023541807A (ja) * | 2020-08-25 | 2023-10-04 | ジェネンテック, インコーポレイテッド | Mhciペプチド結合の特徴づけのためのアッセイおよび試薬 |
CN116410271A (zh) * | 2023-03-13 | 2023-07-11 | 华南农业大学 | H5n1亚型aiv mhc b1限制性t细胞表位肽及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572620B2 (en) * | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
-
2007
- 2007-07-23 CA CA002658559A patent/CA2658559A1/fr not_active Abandoned
- 2007-07-23 WO PCT/US2007/016529 patent/WO2008039267A2/fr active Application Filing
- 2007-07-23 EP EP07861332.0A patent/EP2069376A4/fr not_active Withdrawn
- 2007-07-23 AU AU2007300663A patent/AU2007300663A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11111277B2 (en) | 2016-12-28 | 2021-09-07 | Invvax, Inc. | Influenza vaccines |
US11739127B2 (en) | 2016-12-28 | 2023-08-29 | Invvax, Inc. | Influenza vaccines |
Also Published As
Publication number | Publication date |
---|---|
AU2007300663A1 (en) | 2008-04-03 |
WO2008039267A3 (fr) | 2008-12-31 |
EP2069376A2 (fr) | 2009-06-17 |
EP2069376A4 (fr) | 2013-10-16 |
WO2008039267A2 (fr) | 2008-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2658559A1 (fr) | Induction de reponses immunes cellulaires au virus de la grippe grace a des compositions de peptides et d'acides nucleiques | |
DK2023952T3 (en) | Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions | |
US11439702B2 (en) | Influenza peptides and compositions | |
US9486519B2 (en) | Use of FLT3 ligand for enhancing immune responses in RNA immunization | |
AU2008281384C1 (en) | Multimeric multiepitope influenza vaccines | |
CA2425648A1 (fr) | Peptides de liaison aux hla de classe i et ii et leurs utilisations | |
Reginald et al. | Development of peptide vaccines in dengue | |
McMurry et al. | A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A | |
Frangione-Beebe et al. | Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide | |
AU2022350653A1 (en) | Coronavirus vaccines and methods of use | |
Parzych et al. | Influenza virus specific CD8+ T cells exacerbate infection following high dose influenza challenge of aged mice | |
JP5901084B2 (ja) | ペプチドアジュバント | |
Naskalska et al. | Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron | |
Ilyinskii et al. | Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response | |
JP2022553258A (ja) | インフルエンザウイルスワクチン及びその使用 | |
Isobe et al. | Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant. | |
US20210380644A1 (en) | Peptides for inducing heterosubtypic influenza t cell responses | |
Park et al. | Development of Self-Assembled Protein Nanocage Spatially Functionalized with HA Stalk as a Broadly Cross-Reactive Influenza Vaccine Platform | |
Sundaram | Evaluation of T-cell and B-cell epitopes and design of multivalent vaccines against HTLV-1 diseases | |
Aoshi | 3. 7. Detection of MPT51-specific CD8" Tcells using |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20140723 |